A5065299486- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Neuroendocrine Tumor Research Advances
- Advanced Radiotherapy Techniques
- Prostate Cancer Treatment and Research
- Lung Cancer Research Studies
- Radiation Therapy and Dosimetry
- Neuroblastoma Research and Treatments
- Peptidase Inhibition and Analysis
- Boron Compounds in Chemistry
- Nuclear Physics and Applications
- Lung Cancer Treatments and Mutations
- Hepatocellular Carcinoma Treatment and Prognosis
- Radiation Dose and Imaging
- Mass Spectrometry Techniques and Applications
- Monoclonal and Polyclonal Antibodies Research
- Radioactive Decay and Measurement Techniques
- Atomic and Subatomic Physics Research
- Medical Imaging and Pathology Studies
- Radiomics and Machine Learning in Medical Imaging
- Thyroid Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Cardiac Imaging and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Advances in Oncology and Radiotherapy
Erasmus MC
2015-2024
Erasmus University Rotterdam
2015-2024
Erasmus MC Cancer Institute
2016-2024
Radboud University Nijmegen
2021-2024
Radboud University Medical Center
2021-2024
Radboud Institute for Molecular Life Sciences
2022-2023
University Medical Center
2023
European Association of Nuclear Medicine
2019
Royal Marsden Hospital
2017
Zentralklinik Bad Berka
2015
The accuracy of absorbed dose calculations in personalized internal radionuclide therapy is directly related to the activity (or concentration) estimates obtained at each imaging time points. MIRD Pamphlet no. 23 presented a general overview methods that are required for quantitative SPECT imaging. present document next series isotope-specific guidelines and recommendations follow information was provided 23. This paper focuses on <sup>177</sup>Lu (lutetium) its application...
A framework is proposed for modelling the uncertainty in measurement processes constituting dosimetry chain that are involved internal absorbed dose calculations. The starting point basic model a site of interest as product cumulated activity and factor. In turn, given by area under time–activity curve derived from time sequence values. Each value obtained terms count rate, calibration factor recovery coefficient (a correction partial volume effects). method to determine factor, both which...
The purpose of the EANM Dosimetry Committee is to provide recommendations and guidance scientists clinicians on patient-specific dosimetry. Radiopharmaceuticals labelled with lutetium-177 (177Lu) are increasingly used for therapeutic applications, in particular treatment metastatic neuroendocrine tumours using ligands somatostatin receptors prostate adenocarcinoma small-molecule PSMA-targeting ligands. This paper provides an overview reported dosimetry data these therapies summarises current...
Primary liver tumours (i.e. hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC)) are among the most frequent cancers worldwide. However, only 10-20% of patients amenable to curative treatment, such as resection transplant. Liver metastases frequently caused by colorectal cancer, which accounts for second cancer-related deaths in Europe. In both primary and secondary tumours, radioembolization has been shown be a safe effective treatment option. The vast potential...
Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with target-positive disease can easily be identified PSMA PET imaging. Promising results PSMA-targeted radiopharmaceutical therapy have already been obtained in early-phase studies using various combinations targeting molecules radiolabels. Definitive evidence safety efficacy [177Lu]Lu-PSMA-617 combination standard-of-care has demonstrated metastatic...
Abstract Background In the past years, there has been a notable increase in interest regarding targeted alpha therapy using Ac-225, driven by observed promising clinical anti-tumor effects. As production and technology advanced, availability of Ac-225 is expected to near future, making treatment available patients worldwide. Main body can be labelled different biological vectors, whereby success developing radiopharmaceutical depends heavily on labelling conditions, purity radionuclide...
Adequate dosimetry is mandatory for effective and safe peptide receptor radionuclide therapy (PRRT). Besides the kidneys, bone marrow a potentially dose-limiting organ. The radiation dose to usually calculated according MIRD scheme, where accumulated activity in from radioactivity of radiopharmaceutical blood. This may underestimate absorbed since stem cells express somatostatin receptors. We verified blood-based method by comparing blood with aspirates. Also, we evaluated cross-dose source...
Renal toxicity associated with small-molecule radionuclide therapy has been shown to be dose-limiting for many clinical studies. Strategies maximizing dose the target tissues while sparing normal critical organs based on absorbed and biologic response parameters are commonly used in external-beam therapy. However, radiopharmaceuticals passing though kidneys result a differential rate suborgan elements, presenting significant challenge assessing an accurate dose–response relationship that is...
In peptide receptor radionuclide therapy (PRRT), the bone marrow (BM) is one of dose-limiting organs. The accepted dose limit for BM 2 Gy, adopted from (131)I treatment. We investigated incidence and duration haematological toxicity its risk factors in patients treated with PRRT (177)Lu-DOTA(0)-Tyr(3)-octreotate ((177)Lu-DOTATATE). Also, absorbed estimates were evaluated compared Gy limit.The grade 3 or 4 (according to CTCAE v3.0) analysed. Mean per unit (gigabecquerels) administered...
Peptide receptor radionuclide therapy (PRRT) may induce long-term toxicity to the bone marrow (BM). The aim of this study was analyze persistent hematologic dysfunction (PHD) after PRRT with <sup>177</sup>Lu-DOTATATE in patients gastroenteropancreatic neuroendocrine tumors (GEP NETs). <b>Methods:</b> incidence and course PHD were analyzed 274 GEP NET from a group 367 somatostatin receptor–positive tumors. defined as diagnosis myelodysplastic syndrome (MDS), acute myeloid leukemia (AML),...
Peptide receptor scintigraphy and peptide radionuclide therapy using radiolabeled somatostatin (SSTR) agonists are successfully used in the clinic for imaging treatment of neuroendocrine tumors. Contrary to paradigm that internalization resulting accumulation radiotracers cells is necessary efficient tumor targeting, recent studies have demonstrated superiority SSTR antagonists purposes, despite little no cells. However, comparing therapeutic antitumor effects versus lacking. The aim this...
Prostate-specific membrane antigen (PSMA) is a well-established target for nuclear imaging and therapy of prostate cancer (PCa).Radiolabeled small-molecule PSMA inhibitors are excellent candidates PCa theranostics-they rapidly efficiently localize in tumor lesions.However, high tracer uptake kidneys salivary glands major concerns therapeutic applications.Here, we present the preclinical application I&T, DOTAGA-chelated urea-based inhibitor, SPECT/CT radionuclide PCa. 111 In-PSMA I&T showed...
Because overexpression of the gastrin-releasing peptide receptor (GRPR) has been reported on various cancer types, for example, prostate and breast cancer, targeting this with radioligands might have a significant impact staging treatment GRPR-expressing tumors. NeoBOMB1 is novel DOTA-coupled GRPR antagonist high affinity excellent in vivo stability. The purpose preclinical study was to further explore use theranostic application by determining biodistribution <sup>68</sup>Ga-NeoBOMB1...
Abstract The aim of this standard operational procedure is to standardize the methodology employed for evaluation pre- and post-treatment absorbed dose calculations in 90 Y microsphere liver radioembolization. Basic assumptions include permanent trapping microspheres, local energy deposition method voxel dosimetry, patient–relative calibration activity quantification.The identity 99m Tc albumin macro-aggregates (MAA) biodistribution also assumed. large observed discrepancies some patients...
The EC Directive 2013/59/Euratom states in article 56 that exposures of target volumes nuclear medicine treatments shall be individually planned and their delivery appropriately verified. also mentions medical physics experts should always involved those treatments. Although it is obvious that, practice, every physician physicist follow national rules legislation, the EANM considered necessary to provide guidance on how interpret statements for treatments.For this purpose, proposes...
Abstract Purpose: [177Lu]Lu-PSMA-617 radioligand therapy (177Lu-PSMA) is a novel treatment for metastatic castration-resistant prostate cancer (mCRPC), which could also be applied to patients with hormone-sensitive (mHSPC) PSMA expression. In this prospective study (NCT03828838), we analyzed toxicity, radiation doses, and effect of 177Lu-PSMA in pateints low-volume mHSPC. Patients Methods: Ten progressive mHSPC following local treatment, maximum ten lesions on [68Ga]Ga-PSMA-11...
Radiopharmaceutical therapy (RPT) is a radiation delivery modality that uses radionuclides to irradiate tissues with various forms of ionizing radiation. In most RPT, the radionuclide targeted diseased tissue following systemic administration pharmaceutical circulates throughout body and delivers sites radiopharmaceutical accumulation. Three major classes are used in RPT including beta-particle emitters, alpha-particle Auger-electron emitters. Recent therapeutic successes regulatory approval...